Key result
Serum MCP-1 is not associated with 90-day major cardiovascular events in non-low-risk chest pain.
Why the study?
Prior studies suggested MCP-1 may aid risk stratification in ED chest pain patients, prompting investigation of whether it predicts 90-day MACE in non-low-risk patients.
Does serum monocyte chemoattractant protein-1 (MCP-1), alone or in combination with high-sensitivity troponin T, predict 90-day major adverse cardiovascular events in emergency department patients with non-low-risk acute chest pain and non-elevated contemporary troponins?
Case-Control (n=219)
Expert reviewers adjudicating outcomes and laboratory personnel were blinded to patient details, outcomes, MCP-1, and hs-cTnT results
Yes
Does serum monocyte chemoattractant protein-1 (MCP-1), alone or in combination with high-sensitivity troponin T, predict 90-day major adverse cardiovascular events in emergency department patients with non-low-risk acute chest pain and non-elevated contemporary troponins?
Serum MCP-1 does not predict 90-day MACE and provides inadequate sensitivity and negative predictive value to safely rule out adverse cardiac events in emergency department patients with non-low-risk chest pain and negative serial troponins.
Answers are grounded in this paper and cite their sources.
MCP-1 does not support 90-day risk stratification in non-low-risk chest pain; leaves open its value in prospective or multimarker studies.
BACKGROUND: Prior studies suggest monocyte chemoattractant protein-1 (MCP-1) may be useful for risk stratifying ED patients with chest pain. We hypothesise that MCP-1 will be predictive of 90-day major adverse cardiovascular events (MACEs) in non-low-risk patients. METHODS: A case-control study was nested within a prospective multicentre cohort (STOP-CP), which enrolled adult patients being evaluated for acute coronary syndrome at eight US EDs from 25 January 2017 to 06 September 2018. Patients with a History, ECG, Age, and Risk factor score (HEAR score) ≥4 or coronary artery disease (CAD), a non-ischaemic ECG, and non-elevated contemporary troponins at 0 and 3 hours were included. Cases were patients with 90-day MACE (all-cause death, myocardial infarction or revascularisation). Controls were patients without MACE selected with frequency matching using age, sex, race, and HEAR score or the presence of CAD. Serum MCP-1 was measured. Sensitivity and specificity were determined for cut-off points of 194 pg/mL, 200 pg/mL, 238 pg/mL and 281 pg/mL. Logistic regression adjusting for age, sex, race, and HEAR score/presence of CAD was used to determine the association between MCP-1 and 90-day MACE. A separate logistic model also included high-sensitivity troponin (hs-cTnT). RESULTS: Among 40 cases and 179 controls, there was no difference in age (p=0.90), sex (p=1.00), race (p=0.85), or HEAR score/presence of CAD (p=0.89). MCP-1 was similar in cases (median 191.9 pg/mL, IQR: 161.8-260.1) and controls (median 196.6 pg/mL, IQR: 163.0-261.1) (p=0.48). At a cut-off point of 194 pg/mL, MCP-1 was 50.0% (95% CI 33.8% to 66.2%) sensitive and 46.9% (95% CI 39.4% to 54.5%) specific for 90-day MACE. After adjusting for covariates, MCP-1 was not associated with 90-day MACE at any cut-off point (at 194 pg/mL, OR 0.88 (95% CI 0.43 to 1.79)). When including hs-cTnT in the model, MCP-1 was not associated with 90-day MACE at any cut-off point (at 194 pg/mL, OR 0.85 (95% CI 0.42 to 1.73)). CONCLUSION: MCP-1 is not predictive of 90-day MACE in patients with non-low-risk chest pain.
No takes yet. Share an insight, caveat, or question.
Ashburn et al. (2021) conducted a case-control in Non-low-risk acute chest pain being evaluated for acute coronary syndrome (n=219). Elevated serum monocyte chemoattractant protein-1 (MCP-1) at cut-off ≥194 pg/mL vs. Serum MCP-1 below cut-off (<194 pg/mL) or non-MACE controls was evaluated on 90-day major adverse cardiovascular events (MACE: composite of all-cause mortality, myocardial infarction, or coronary revascularisation) (OR 0.88, 95% CI 0.43 to 1.79, p=0.48). Serum MCP-1 was not associated with 90-day major cardiovascular events in patients with non-low-risk chest pain.
Synapse has enriched 10 related papers. Consider them for comparative context: